CDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo

Loading news article.

CDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo | WAPE

CDT Equity Partners With QIMA Life Sciences To Develop Several Of The Company's Autoimmune Skin Disease Assets, Including Novel Tapinarof Combinations In Psoriasis And Vitiligo

Article summary

Related companies

Analyzed by WAPE AI.

Comments —